Return to search

Partners Group, PSP to buy Cerba Healthcare

Partners Group and PSP Investments have agreed to buy Cerba HealthCare. Financial terms weren’t announced. PAI Partners is the seller. Cerba, of Paris, operates clinical pathology laboratories.


Partners Group and PSP Investments to acquire Cerba HealthCare, a leading European operator of

clinical pathology laboratories, from PAI Partners

Partners Group, the global private markets investment manager, acting on behalf of its clients, and the

Public Sector Pension Investment Board (“PSP Investments”), one of Canada’s largest pension

investment managers, have agreed to acquire European medical laboratory services operator, Cerba

HealthCare (“Cerba”, “the Company”). The company is being acquired from PAI Partners, a leading

European private equity firm, and the company’s clinical pathologists and managers.

Founded in 1967 and headquartered in Paris, France, Cerba is a leading operator of clinical pathology

laboratories, with a number one position in France and strong market positions in Belgium and

Luxembourg. The majority of Cerba’s revenues are generated via routine lab tests. The company also

focuses on specialty lab testing for more complex medical diagnoses and testing services for clinical

trials. Cerba’s clients include private patients, physicians, labs, private and public hospitals, retirement

and nursing homes, and pharmaceutical and biotech companies. The company employs almost 4,300

people, including 350 biologists, and generated revenues of approximately EUR 630 million in 2016.

Following the completion of the acquisition, which is subject to the legislative information process

involving the Company’s works council and regulatory approvals, Partners Group and PSP

Investments will work with Cerba’s management team, led by CEO Catherine Courboillet, to support

the numerous growth opportunities of the business. These include the continuation of the Company’s

highly successful M&A strategy within the French market and internationally, as well as the

acceleration of organic growth and development in other segments.

Catherine Courboillet, CEO, Cerba HealthCare, states: “Cerba has enjoyed tremendous growth in the

past decade. When we approached the transition to new ownership, we focused on finding partners

who would not only support a continuation of this pace of growth, but could also bring valuable

support in international development. We believe we have found the right partners in Partners Group

and PSP Investments and look forward to working together with them to further build on Cerba’s

market-leading position.”

Kim Nguyen, Managing Director, Private Equity Europe, Partners Group, comments: “Cerba is a

resilient market leader in a highly attractive and fragmented sub-sector of the healthcare industry. The

unique fully integrated business model means that Cerba is ideally positioned to further consolidate

the French market and accelerate organic growth. We have been impressed by Catherine Courboillet’s strategy of entering new business areas and optimizing Cerba’s retail portfolio. We look

forward to working together with Catherine and her team and our investment partner PSP

Investments to continue strengthening Cerba’s market leadership position.”

Simon Marc, Managing Director, Private Equity (Europe), PSP Investments, adds: “Over the last couple

of decades, Catherine Courboillet and her team have grown Cerba HealthCare into the leading private

medical biology laboratory business in France. Cerba has developed a unique positioning in its markets

on the back of its widely recognized medical and industry expertise and we are excited about the

growth prospects of the company. As a provider of long-term strategic capital, we look forward to

working with Partners Group, Catherine and the management team to support Cerba’s growth in

France and internationally.”


About Partners Group

Partners Group is a global private markets investment management firm with over EUR 54 billion

(USD 57 billion) in investment programs under management in private equity, private real estate,

private infrastructure and private debt. The firm manages a broad range of customized portfolios for

an international clientele of institutional investors. Partners Group is headquartered in Zug,

Switzerland and has offices in San Francisco, Denver, Houston, New York, São Paulo, London,

Guernsey, Paris, Luxembourg, Milan, Munich, Dubai, Mumbai, Singapore, Manila, Shanghai, Seoul,

Tokyo and Sydney. The firm employs over 900 people and is listed on the SIX Swiss Exchange (symbol:

PGHN) with a major ownership by its partners and employees.

About PSP Investments

The Public Sector Pension Investment Board (PSP Investments) is one of Canada’s largest pension

investment managers with C$125.8 billion of net assets under management as at September 30, 2016.

It manages a diversified global portfolio composed of investments in public financial markets, private

equity, real estate, infrastructure, natural resources and private debt. Established in 1999, PSP

Investments manages net contributions to the pension funds of the federal Public Service, the

Canadian Armed Forces, the Royal Canadian Mounted Police and the Reserve Force. Headquartered

in Ottawa, PSP Investments has its principal business office in Montréal and offices in New York and

London. or Twitter @InvestPSP.

About Cerba HealthCare

The Group has a presence in three complementary segments: – Routine medical biology, mainly in

France, Belgium and Luxembourg, with more than 300 specimen collection centres and 50 technical

platforms. – Specialised medical biology, through its historic laboratory serving more than 50 countries

in Europe, Africa and Middle East. – Clinical trial biology — essential in the process of development of

new molecules by the pharmaceutical and biotechnology industry — through its subsidiaries set up across the five continents. Recently the Group diversified in the veterinary biology market by creating Cerba Vet, a dedicated entity. Cerba has almost 4,300 employees including 350 biologists. In 2015, its consolidated turnover was EUR 605 million.